BrightSpring Health Services (BTSG) is back in focus after reporting fourth quarter and full year 2025 results alongside fresh 2026 revenue guidance, giving investors new data on profitability, growth, and near term expectations.

The earnings beat and new 2026 revenue guidance come after a 90 day share price return of 10.98% and a 1 year total shareholder return of 108.68%. Recent short term softness therefore contrasts with strong longer term momentum at a last close of $40.13.

If this earnings release has you thinking about where growth in healthcare could show up next, it may be worth scanning our list of 29 healthcare AI stocks as a starting point for further ideas.

With shares up strongly over the past year, a price target implying only single digit upside, and fresh 2026 guidance now public, the real question is whether BrightSpring still offers value or if the market is already pricing in future growth.

Most Popular Narrative: 4.3% Undervalued

BrightSpring Health Services' most followed narrative points to a fair value of $41.93, only slightly above the last close at $40.13, putting the focus firmly on the assumptions behind that gap.

The analysts have a consensus price target of $28.708 for BrightSpring Health Services based on their expectations of its future earnings growth, profit margins and other risk factors. However, there is a degree of disagreement amongst analysts, with the most bullish reporting a price target of $41.0, and the most bearish reporting a price target of just $25.0.

Read the complete narrative. Read the complete narrative.

Want to see why the most popular fair value sits above both the consensus target and the current price? Earnings power, margin assumptions, and a future valuation multiple all pull in different directions, and the full narrative explains how they are combined.

Result: Fair Value of $41.93 (UNDERVALUED)

However, the fair value story still rests on key swing factors, including access to limited distribution drugs and execution risks in scaling Provider Services under changing reimbursement and staffing conditions.

Another Angle On Valuation

There is a wrinkle here. While the narrative fair value suggests BrightSpring looks 4.3% undervalued at $41.93, the P/E picture is very different. At 75.1x earnings versus a fair ratio of 32.1x, the stock screens as expensive against both peers and the wider US Healthcare sector at 23.6x. Is the premium justified, or is the story running ahead of itself?

Next Steps

Feeling torn between the upbeat fair value story and that rich P/E? It helps to move fast, look at the full picture, and weigh both the potential and the risks for yourself with 3 key rewards and 2 important warning signs

Ready to hunt for your next idea?

If BrightSpring has sharpened your thinking, do not stop here. The screener can help you quickly spot other opportunities that fit your style and risk comfort.

• Target potential mispricings by checking companies that currently look cheaper than their fundamentals suggest through our 54 high quality undervalued stocks.
• Zero in on income ideas by reviewing companies in the 15 dividend fortresses that currently offer higher yields with a focus on durability.
• Prioritize capital preservation by scanning the 80 resilient stocks with low risk scores for businesses that score better on stability and downside risk.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.